Alicia Morgans: Hi. My name is Alicia Morgans and I’m a GU medical oncologist at the Dana-Farber Cancer Institute in Boston, in the United States. I am so excited to talk today with a wonderfully inspirational individual, Mr. Cam Upton, who was diagnosed with prostate cancer at 43 years old, is a business owner and […]
Immune checkpoint blockade (ICB) is associated with durable responses in a select group of patients with advanced cancer achieving. However, attempts to define biomarkers to identify this subgroup of exceptional responders have been elusive. Pan-tumor predictive biomarkers to PD-L1 blockade are lacking.
San Francisco, CA (UroToday.com) — Boston Scientific announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based medical solutions, from an affiliate of Baring Private Equity Asia (BPEA). The Lumenis surgical business includes premier laser systems, fibers, and accessories used for urology and otolaryngology […]
Background: Active treatments for prostate cancer are well known to result in several adverse effects such as fatigue, depression and anxiety symptoms, impacting the overall quality of life (QoL) and wellbeing of a considerable proportion of patients. Resistance-based exercise interventions have shown positive effects to reduce or mitigate these treatment-related side effects. However, the minimal […]
Doctor: “You have prostate cancer.” Patient: “Doctor, that’s awful. What can I do to help it grow slower and feel better?” Doctor: “Eat right and exercise.” Patients: “How much exercise should I do?” Doctor: “I don’t know.” While the above is a fictitious discussion between doctor and patient, my guess is that similar discussions occur […]
Study Abstract Accepted for Presentation at 2021 AUA San Francisco, CA (UroToday.com) — A study to help understand the implications of Next-Generation DNA Sequencing (NGS) in the diagnosis and treatment of Urinary Tract Infections (UTIs) and other inflammatory urological conditions has been completed, and results will be presented at the September, 2021 AUA Conference. The study, […]
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical responses in subsets of cancer patients across multiple indications, including non-small cell lung cancer (NSCLC), urothelial carcinoma (UC) and renal cell carcinoma (RCC).
JAMA network open. 2021 May 03*** epublish *** Christopher J D Wallis, Zachary Klaassen, William C Jackson, Robert T Dess, Zachery R Reichert, Yilun Sun, Daniel E Spratt Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Investigating supportive care (SC) needs and utilization/willingness to use SC services from diagnosis to one year after radical cystectomy in bladder cancer (BC) patients. MATERIALS & METHODS: A longitudinal cohort study was conducted in 90 BC patients at Ghent/Leuven University Hospitals between April 2017 and December 2020.
Patients with advanced clear cell renal cell carcinoma (ccRCC) have a poor prognosis and lack effective prognostic biomarkers. N6-methyladenosine-related lncRNAs (m6A-related long noncoding RNAs [lncRNAs]) have been confirmed to be associated with the development of multiple tumors, but its role in ccRCC is not clear.
